4月9日 - ** 癌症药物开发商Tempest Therapeutics TPST.O的股票在延时交易中上涨9%至7.79美元
** TPST称 (link)，该公司正在探索合并或合作等战略选择，以推进其癌症治疗项目。
** 公司的产品线包括肝癌先导药物 amezalpat 和治疗罕见遗传性疾病家族性腺瘤性息肉病的 TPST-1495
** Amezalpat 获得了美国 FDA 的 "孤儿药 "和 "快速通道 "认定
** 截至上一交易日收盘，股价累计下跌 34
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.